This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.

The present invention relates to an influenza virus surface protein-derived recombinant hemagglutinin (HA) protein forming a trimer and use thereof, and more specifically to a recombinant vector for producing an influenza virus surface protein-derived HA protein forming a trimer, a transformant transformed by the recombinant vector, a method for producing an influenza virus surface protein-derived HA protein forming a trimer using the recombinant vector, an influenza virus surface protein-derived HA protein produced by the method, and the use thereof in preventing, ameliorating or treating influenza virus-infected disease.

Use of a superantigen in mucosal allergen specific immune therapy (ASIT) in a human being to enhance the effect thereof. In order to enhance the effect of the mucosal ASIT, the superantigen is mucosally administered before, or with, the allergen to the human being.

An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine against toxoplasmosis, a diseases caused by infection with T. gondii.

The invention pertains to a vaccine for use in protecting a pig against an infection with porcine endemic diarrhea virus (PEDV), the vaccine comprising non-live PEDV antigen and a non-metabolizable oil containing adjuvant, wherein the total amount of oil in the vaccine is less than 50% v/v, by administration of a dose of the antigen corresponding to at least 3.0E6 TCID50 killed whole PEDV. The invention also pertains to a method of protecting a pig against an infection with porcine endemic diarrhea virus.

An object of the present invention is to optimize, and to increase the accumulation amount of, GP5 antigen, in order to enhance the performance of a PRRS vaccine. The present invention provides a fusion protein comprising an ectodomain (ectGP5) of Glycoprotein 5 (GP5) of porcine reproductive and respiratory syndrome (PRRS) virus, and an adjuvant protein.

The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.

This disclosure features compositions that include two or more staphylococcal toxoids and are useful for inducing protective immune responses against staphylococcal diseases.

Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.